Lowell Anthony

Summary

Affiliation: Louisiana State University Health Sciences Center
Country: USA

Publications

  1. doi Irinotecan toxicity
    Lowell Anthony
    Louisiana State University Health Sciences Center, Stanley S Scott Cancer Center, New Orleans, Louisiana 70012, USA
    Curr Opin Support Palliat Care 1:35-9. 2007
  2. pmc From somatostatin to octreotide LAR: evolution of a somatostatin analogue
    Lowell Anthony
    Louisiana State University, New Orleans, USA
    Curr Med Res Opin 25:2989-99. 2009
  3. doi Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period
    Lowell Anthony
    Division of Hematology Oncology, Louisiana State University, New Orleans, LA 70112, USA
    Pancreas 40:987-94. 2011
  4. pmc Surgical treatment of advanced-stage carcinoid tumors: lessons learned
    J Philip Boudreaux
    Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
    Ann Surg 241:839-45; discussion 845-6. 2005
  5. ncbi New thoughts on the pathobiology of regimen-related mucosal injury
    Lowell Anthony
    The Stanley S Scott Cancer Center, LSUHSC, New Orleans, LA, USA
    Support Care Cancer 14:516-8. 2006
  6. ncbi Cytoreductive surgery in patients with advanced-stage carcinoid tumors
    Seza A Gulec
    Department of Surgery, Louisiana State University Health Sciences Center, New Orleans 70119, USA
    Am Surg 68:667-71; discussion 671-2. 2002
  7. ncbi New strategies for the prevention and reduction of cancer treatment-induced diarrhea
    Lowell Anthony
    Division of Hematology Oncology, Louisiana State University, New Orleans, LA, USA
    Semin Oncol Nurs 19:17-21. 2003
  8. ncbi A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial
    Stephen H Rosenoff
    Oncology and Hematology Associates US Oncology, Roanoke, Virginia 24014 2419, USA
    J Support Oncol 4:289-94. 2006

Collaborators

Detail Information

Publications8

  1. doi Irinotecan toxicity
    Lowell Anthony
    Louisiana State University Health Sciences Center, Stanley S Scott Cancer Center, New Orleans, Louisiana 70012, USA
    Curr Opin Support Palliat Care 1:35-9. 2007
    ....
  2. pmc From somatostatin to octreotide LAR: evolution of a somatostatin analogue
    Lowell Anthony
    Louisiana State University, New Orleans, USA
    Curr Med Res Opin 25:2989-99. 2009
    ..The majority of GEP-NETs are carcinoid tumors whose syndrome is caused by the hypersecretion of biogenic amines, peptides and polypeptides responsible for the principal symptoms of diarrhea and flushing...
  3. doi Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period
    Lowell Anthony
    Division of Hematology Oncology, Louisiana State University, New Orleans, LA 70112, USA
    Pancreas 40:987-94. 2011
    ..This retrospective study evaluated physician practice patterns in the medical management of patients with neuroendocrine tumors (NETs) treated with octreotide LAR...
  4. pmc Surgical treatment of advanced-stage carcinoid tumors: lessons learned
    J Philip Boudreaux
    Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
    Ann Surg 241:839-45; discussion 845-6. 2005
    ..To evaluate clinical outcomes in a large group of advanced-stage carcinoid patients (stage IV) following multimodal surgical therapy...
  5. ncbi New thoughts on the pathobiology of regimen-related mucosal injury
    Lowell Anthony
    The Stanley S Scott Cancer Center, LSUHSC, New Orleans, LA, USA
    Support Care Cancer 14:516-8. 2006
    ..e. gender, underlying systemic disease, race) and tissue specific (i.e. epithelial type, intrinsic endocrine system, local microbial environment, function) factors...
  6. ncbi Cytoreductive surgery in patients with advanced-stage carcinoid tumors
    Seza A Gulec
    Department of Surgery, Louisiana State University Health Sciences Center, New Orleans 70119, USA
    Am Surg 68:667-71; discussion 671-2. 2002
    ..Aggressive surgical exploration and tumor debulking could be performed with significantly improved symptomatic outcome and relatively minor complications. Longer follow-up is needed for assessment of effect on survival...
  7. ncbi New strategies for the prevention and reduction of cancer treatment-induced diarrhea
    Lowell Anthony
    Division of Hematology Oncology, Louisiana State University, New Orleans, LA, USA
    Semin Oncol Nurs 19:17-21. 2003
    ..To describe possible new strategies for the prevention of CTID...
  8. ncbi A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial
    Stephen H Rosenoff
    Oncology and Hematology Associates US Oncology, Roanoke, Virginia 24014 2419, USA
    J Support Oncol 4:289-94. 2006
    ..Adverse events were balanced between the two groups. No specific recommendations can be made from this trial regarding the use of 30 mg versus 40 mg of octreotide LAR for CID...